Babesiosis Treatment Market

Babesiosis Treatment Market Snapshot (2023 to 2033)

The global Babesiosis Treatment market size is expected to be valued at USD 1.21 Billion in 2023. With the continuous improvements in drugs and biotechnology for the treatment of babesiosis, the overall scope for Babesiosis Treatment Market is projected to grow at a CAGR of 5.0% between 2023 and 2033, totaling around USD 1.98 Billion by 2033.

Data Points	Key Statistics
Babesiosis Treatment Market Value 2023	USD 1.21 Billion
Babesiosis Treatment Market Projected Value (2033)	USD 1.98 Billion
Babesiosis Treatment Market CAGR (2023 to 2033)	5.0%

According to the analysis of Future Market Insights, major factors such as an increase in the number of cases of Lyme disease, and the extensive possibility for the growth of antibiotics for curing patients having babesiosis are anticipated to fuel the growth of the babesiosis treatment market during the analysis period. For instance, International Lyme and Associated Disease Society (ILADS) recommends customized antibiotic treatment for the patients depending on their response to treatment, as Lyme disease is hard to diagnose, which results in persistent infection. However, the treatment of antibiotics cannot reduce the infection of Lyme disease, which in turn gives a wider scope for the development of ideal antibiotic treatment of babesiosis.

Additionally, in March 2018, the USA Food and Drug Administration approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay (AFIA), for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, as well as the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples. These tests were intended to be used as donor screening tests on samples from individual human donors, including volunteer donors of whole blood and blood components, as well as living organ and tissue donors.

Babesiosis Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for Babesiosis Treatment is projected to increase at a CAGR of 5.0% during the forecast period between 2023 and 2033, reaching a total of USD 1.98 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, the demand witnessed significant growth, registering a CAGR of 2.8%.

According to Future Market Insights, a market research and competitive intelligence provider, the Babesiosis Treatment market was valued at USD 1.16 Billion in 2022.

The increasing number of ongoing innovations in the medicinal industry in the area of immunization is a major factor that is projected to increase the frequency of prevention of babesiosis in the forthcoming years. The development of a vaccine to protect individuals from infected ticks is a continuing goal of medical experts and researchers, as the number of babesiosis cases increases globally.

For instance, doctors from the UMASS Medical School in the USA have reportedly been working on producing a medicine, PrEP (pre-exposure prophylaxis) for the cure of babesiosis. The medication has the ability to give patients antibodies against babesiosis. Phase 1 clinical studies for the treatment of babesiosis are now taking place, and a market launch is anticipated for 2023.

Which Drivers underpin Babesiosis Treatment Industry Expansion?

Increasing Cases of Babesiosis to Fuel the Market Growth

The growing cases of babesiosis disease among people that can cause severe problems with joints, the neurological system, exhaustion, fever, skin rashes, etc., and the rising temperatures and climate change that can increase the range of deer ticks’ habitat are the major factors that are likely to augment the growth of the babesiosis treatment market in the coming years.

Moreover, there are numerous factors influencing how babesiosis disease is spreading. Tick activity is dependent on shorter winters which may also prolong the time that ticks are present if temperatures are over a specific threshold and are each active. The increase in the number of Lyme diseases is another factor driving the market growth.

Surging Research and Development (R&D) Activities for Proper Treatment of Babesiosis to Accelerate the Market Growth

Researchers have discovered that hygromycin A, a neglected antibiotic, selectively destroys the germs that cause babesiosis disease. Cefotaxime and azlocillin are the two medications used in the novel treatment. The majority of doctors believe that doxycycline is the best medication for treating babesiosis. These are the usual treatments for Lyme disease and babesiosis in its early stages. These typically consist of amoxicillin or cefuroxime for adults, younger children, pregnant or nursing women, and children older than 8, as well as doxycycline for adults and children older than 8.

Furthermore, the broad-spectrum antibiotics used to treat babesiosis disease have an impact on the human gut microbiota and have the potential to cause non-target bacteria to become more resistant to them. Hence, healthcare professionals have been looking for a substance that would have a more focused range of activity against B. burgdorferi, the bacteria that causes babesiosis. The aforementioned factors are expected to boost market growth during the forecast period.

Which Factors are limiting the Growth of Babesiosis Treatment Market?

Lack of Awareness Regarding Babesiosis to Restrain the Market

One of the major factors hindering the growth of the babesiosis treatment market over the analysis period includes the lack of awareness regarding the illness. The high cost of babesiosis therapeutics is another factor that is expected to impede market growth.

Babesiosis can spread to other parts of the body for many more months to years, if remains untreated after infection, triggering arthritis when bacteria of the disease enter into the tissue of joints and cause hypersensitivity reaction and neurological problems such as unresponsiveness, discomfort, weakness, and facial palsy/ (facial muscle paralysis).

Babesiosis is produced by parasites that pollute red blood cells and Colorado tick fever. Colorado Tick Fever (CTF) is an unusual type of viral disease by the chewing of a diseased Rocky Mountain wood tick which generally originated in the western part of Canada and the USA There are no medicines or vaccines to prevent infection of CTF. Thus, all the aforementioned factors are likely to restrain the market growth over the forecast period.

Misdiagnosis of Babesiosis to Limit the Market Growth

The babesiosis treatment market is hampered due to a lack of biological biomarkers and treatment regimens, which makes it difficult to be diagnosed. In addition, there is no standardized protocol for treatment. Since no combination of medications will entirely cure the infection, the patient may experience an immunological reaction that keeps the infection going.

As the patients having babesiosis exhibit similar symptoms including fever and body aches, the condition is frequently mistaken for a common rash or any seasonal allergy. Also, factors such as lack of awareness regarding the prevalence and symptoms of babesiosis disease are other factors that are anticipated to limit the market expansion in the forthcoming years.

Region-wise Insights

Will North America Continue Dominance in the Global Babesiosis Treatment Market?

Enhanced Healthcare Expenditure in the Region to Fuel the Market Growth

The Babesiosis Treatment Market in North America is expected to accumulate the highest market share of 43% in 2023.

Factors such as innovative healthcare set-ups as well as improved healthcare expenditure in the region are expected to accelerate the regional market growth over the analysis period. In addition, due to a warmer climate, wet winter, and more civilization, people in the region are more prone to catch the disease. As per the Centers for Disease Control and Prevention (CDC), the USA reports 20,000 to 30,000 confirmed cases of Lyme disease each year, which causes babesiosis.

The market in this region is expanding primarily as a result of the increased prevalence of diseases spread by ticks or other vectors. In addition, the high healthcare expenditure and good quality medical facilities are expected to fuel the market growth in the region. Also, the majority of the population in North America has insurance coverage to claim this type of expensive treatment, which in turn is projected to boost regional market growth. The region is expected to hold the highest CAGR of 4.9% during the forecast period.

How Will the Growth of the Babesiosis Treatment Market unfold in Asia Pacific?

Rising Awareness Regarding Available Treatment Options in the Region to Fuel the Market Growth

The Babesiosis Treatment Market in Asia Pacific is expected to accumulate the highest market share of 42% in 2023.

The emergence of vector-borne diseases in the Asia Pacific is one of the major factors that are likely to escalate the regional market growth over the analysis period. According to a report by the National Library of Medicine, in 2015, human cases of Lyme disease caused by genospeciesB. garinii, B. afzelii, and Borrelia valaisiana were reported in most provinces of China.

Additionally, factors such as a rise in awareness about emerging tick-borne pathogens are expected to stimulate market growth in the future. The growth of the market is also attributed to the growing need for advanced healthcare services amongst individuals in the region, backed by the rising population across several countries such as India, China, and Japan. The region is expected to hold the highest CAGR of 4.8% during the forecast period.

Category-wise Insights

By Route of Administration, which Babesiosis Treatment Category will remain prominent?

Oral Segment to beat Competition in Untiring Market

On the basis of the route of administration, the global Babesiosis Treatment market is dominated by the Oral Segment, which accounts for a share of 45%. The segment is expected to hold a CAGR of 4.9% over the analysis period.

Oral drug delivery is the most common route of administration, attributed to having features such as more patient adherence, easy to take, and no requirement for a clean and sophisticated environment. The oral route of administration is more cost-effective than

Injectable and others routes available in the market. Oral Doxycycline is more efficient than other routes and is comparatively proven better in clinical trials. The oral route is beneficial for persons having joint swelling and for erythema migrans, which are the early symptoms of babesiosis.

By Distribution Channel, which Babesiosis Treatment Category dominates?

Hospital Pharmacy Segment to Drive the Babesiosis Treatment Market

Based on the Distribution Channel, the hospital pharmacy segment is expected to witness a significant growth of 44% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.8% CAGR over the analysis period.

The expansion of the segment can be attributed to an increase in outpatient hospital visits and admissions by patients suffering from diseases such as babesiosis. Purchasing medication from hospital pharmacies is simple and handy for patients, since they may obtain medications on time. All these factors are anticipated to accelerate the scope of the market in the coming time.

The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?

Babesiosis Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,

• In August 2021, Vectech, a startup developing data and analytics tools for disease-carrying organisms, such as mosquitoes and ticks, was awarded a USD295k Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The award will fund the research and development of an optics and computer vision system for the automated identification of the top nine tick vectors in the USA. The research complements Vectech’s innovative mosquito identification system, currently undergoing beta testing in mosquito control organizations throughout the USA.
• In May 2021, Wylo Biosciences announced that the company is working on manufacturing tick-test kits as easy and portable as pregnancy tests. The test will immediately tell if a tick is infected with one of four tick-borne diseases: Lyme disease, babesia, anaplasmosis, and ehrlichiosis.
• In March 2021, the Mayo Clinic released a new article in JCM (Journal of Microbiology) by the American Society for Microbiology suggesting RipSeq can be used as a new way of detecting tick-borne diseases such as Lyme disease. The RipSeq NGS, which is a pathogen identification software, was launched by a local Santa Cruz startup Pathogenomix several years ago.

Who are the Leading Players in the Babesiosis Treatment Market?

Prominent players in the Babesiosis Treatment market are GlaxoSmithKline LLC, Amneal Pharmaceuticals LLC., Apotex, Glenmark, Hetero, Lupin, Camber Pharmaceuticals, Inc., Galderma, Fresenius Kabi, Abbott, Pfizer, Inc., Taro Pharmaceutical Industries, Otto Pharmaceutical, Medpharma, Endure Medical, Huajin Pharmaceutical, Mylan Pharmaceutical Inc., Tabuk Pharmaceutical, Aurobindo Pharma Ltd., and Epic Pharma LLC., among others.

Recent Developments:

• In August 2022, the pharmaceutical companies Pfizer and Valneva announced the beginning of phase 3 clinical trials for the world’s only Lyme disease vaccine, VLA15. VLA15 is a multivalent vaccine, targeting the six most common serotypes of Lyme disease-causing Borrelia burgdorferi bacteria’s outer surface protein, OspA.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.0% from 2023 to 2033
Market Value in 2023	USD 1.21 Billion
Market Value in 2033	USD 1.98 Billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Type, Route of Administration, End-Users, Distribution Channel, Region
Regions Covered	North America; Europe; Europe; Latin America; Middle East & Africa
Key Countries Profiled	The USA, Canada, Brazil, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	GlaxoSmithKline LLC; Amneal Pharmaceuticals LLC; Apotex; Glenmark; Hetero; Lupin; Camber Pharmaceuticals, Inc.; Galderma; Fresenius Kabi; About; Pfizer, Inc.; aro Pharmaceutical Industries; Otto Pharmaceutical; Medpharma; Endure Medical; Huajin Pharmaceutical; Mylan Pharmaceutical Inc.; Tabuk Pharmaceutical; Aurobindo Pharma Ltd; Epic Pharma LLC.

Key Segments Covered in the Babesiosis Treatment Industry Analysis

Babesiosis Treatment Market by Drug Type:

• Branded
• Generic

Babesiosis Treatment Market by Route of Administration:

• Oral
• Injectable
• Others

Babesiosis Treatment Market by End-Users:

• Hospitals
• Academic Research Institutes
• Home Healthcare
• Others

Babesiosis Treatment Market by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Babesiosis Treatment Market by Region:

• North America
• Europe
• Europe
• Latin America
• Middle East & Africa

Frequently Asked Questions

What is the Current Valuation of the Babesiosis Treatment Market?

The babesiosis treatment market registers USD 1.21 billion in revenue in 2023.

What is the Estimated Babesiosis Treatment Market Size Envisioned by 2033?

The global babesiosis treatment market revenue is projected to exceed USD 1.98 billion by 2033.

What CAGR is Foreseen for the Babesiosis Treatment Market in the Upcoming Decade?

Adoption of babesiosis treatment is anticipated to upsurge at a 5.0% CAGR through 2033.

Which Country Underscores Substantial Revenue Prospects for Babesiosis Treatment?

Given its advanced healthcare infrastructure, the United States stands out as a country with substantial revenue prospects for babesiosis treatment.

What was the Babesiosis Treatment Market's Past Record like?

The babesiosis treatment market secured USD 1.16 billion in revenue in 2022, registering a slow-paced 2.8% CAGR.